tetano
Editor, Senior Moderator
Lancet Reg Health Southeast Asia
. 2022 Dec 13;100129.
doi: 10.1016/j.lansea.2022.100129. Online ahead of print.
An Observational Multi-centric COVID-19 Sequelae Study among Health Care Workers
Ajay Kumar Shukla[SUP] 1 [/SUP], Shubham Atal[SUP] 1 [/SUP], Aditya Banerjee[SUP] 1 [/SUP], Ratinder Jhaj[SUP] 1 [/SUP], Sadasivam Balakrishnan[SUP] 1 [/SUP], Preeta Kaur Chugh[SUP] 2 [/SUP], Denis Xavier[SUP] 3 [/SUP], Atiya Faruqui[SUP] 3 [/SUP], Aakanksha Singh[SUP] 3 [/SUP], Ramasamy Raveendran[SUP] 4 [/SUP], Jayanthi Mathaiyan[SUP] 4 [/SUP], Jeevitha Gauthaman[SUP] 4 [/SUP], Urwashi I Parmar[SUP] 5 [/SUP], Raakhi K Tripathi[SUP] 5 [/SUP], Sandhya K Kamat[SUP] 5 [/SUP], Niyati Trivedi[SUP] 6 [/SUP], Prashant Shah[SUP] 6 [/SUP], Janki Chauhan[SUP] 6 [/SUP], Harihar Dikshit[SUP] 7 [/SUP], Hitesh Mishra[SUP] 7 [/SUP], Rajiv Kumar[SUP] 7 [/SUP], Dinesh Kumar Badyal[SUP] 8 [/SUP], Monika Sharma[SUP] 9 [/SUP], Mamta Singla[SUP] 10 [/SUP], Bikash Medhi[SUP] 11 [/SUP], Ajay Prakash[SUP] 11 [/SUP], Rupa Joshi[SUP] 11 [/SUP], Nabendu S Chatterjee[SUP] 12 [/SUP], Jerin Jose Cherian[SUP] 12 [/SUP], Ved Prakash Kamboj[SUP] 13 [/SUP], Nilima Kshirsagar[SUP] 14 [/SUP]
Affiliations
Abstract
India have seen more than 43 million confirmed cases of COVID-19 as of April 2022, with a recovery rate of 98.8%, resulting in a large section of the population including the healthcare workers (HCWs), susceptible to develop post COVID sequelae. This study was carried out to assess the nature and prevalence of medical sequelae following COVID-19 infection, and risk factors, if any, associated with them. Methods: This was an observational, multicenter cross-sectional study conducted at eight tertiary care centers. The consenting participants were HCWs between 12-52 weeks post discharge after COVID-19 infection. Data on demographics, medical history, clinical features of COVID-19 and various symptoms of COVID sequelae was collected through specific questionnaire. Finding: Mean age of the 679 eligible participants was 31.49 ± 9.54 years. The overall prevalence of COVID sequelae was 30.34%, with fatigue (11.5%) being the most common followed by insomnia (8.5%), difficulty in breathing during activity (6%) and pain in joints (5%). The odds of having any sequelae were most significantly higher among participants who had moderate to severe COVID-19 (OR 6.51; 95% CI 3.46 - 12.23) and lower among males (OR 0.55; 95% CI 0.39-0.76). Besides these, other predictors for having sequelae were age (≥ 45 years), presence of any comorbidity (especially hypertension and asthma), category of HCW (non-doctors vs doctors) and hospitalisation due to COVID-19. Interpretation: Approximately one-third of the participants experienced COVID sequelae. Severity of COVID illness, female gender, advanced age, co-morbidity were significant risk factors for COVID sequelae. Funding: This work is a part of Indian Council for Medical Research (ICMR)- Rational Use of Drugs network. No additional financial support was received from ICMR to carry out the work, for study materials, medical writing, and APC. FundingIndian Council of Medical Research (ICMR) through its Task Force Project on Rational Use of Medicines.
Keywords: ACE2, Angiotensin-converting enzyme 2; AE, Adverse events; Anxiety, and Stress Scale-21; BMI, Body mass index; CAD, Coronary artery disease; CI, Confidence interval; COVID sequelae; COVID-19; COVID-19, Corona virus disease 2019; CTRI, Clinical Trials Registry- India; DASS-21, Depression; ENT, Ear, nose, and throat; GERD, Gastroesophageal reflux disease; Govt. of India, OR; HCQ, Hydroxychloroquine; HCW, Health care worker; ICMR, Indian council of medical research; ICMR-RUMC; MOHFW, Ministry of Health and Family Welfare; NICE, National Institute for Health and Clinical Excellence; Odds ratio, PCOS; Polycystic Ovarian Disease, PLOG; Polymerase gamma-related disorders, p-value: Probability value; RHD, Rheumatic heart disease; RUMC, Rational use of medicine center; SARS-CoV-2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; WHO, World Health Organization; long COVID.
. 2022 Dec 13;100129.
doi: 10.1016/j.lansea.2022.100129. Online ahead of print.
An Observational Multi-centric COVID-19 Sequelae Study among Health Care Workers
Ajay Kumar Shukla[SUP] 1 [/SUP], Shubham Atal[SUP] 1 [/SUP], Aditya Banerjee[SUP] 1 [/SUP], Ratinder Jhaj[SUP] 1 [/SUP], Sadasivam Balakrishnan[SUP] 1 [/SUP], Preeta Kaur Chugh[SUP] 2 [/SUP], Denis Xavier[SUP] 3 [/SUP], Atiya Faruqui[SUP] 3 [/SUP], Aakanksha Singh[SUP] 3 [/SUP], Ramasamy Raveendran[SUP] 4 [/SUP], Jayanthi Mathaiyan[SUP] 4 [/SUP], Jeevitha Gauthaman[SUP] 4 [/SUP], Urwashi I Parmar[SUP] 5 [/SUP], Raakhi K Tripathi[SUP] 5 [/SUP], Sandhya K Kamat[SUP] 5 [/SUP], Niyati Trivedi[SUP] 6 [/SUP], Prashant Shah[SUP] 6 [/SUP], Janki Chauhan[SUP] 6 [/SUP], Harihar Dikshit[SUP] 7 [/SUP], Hitesh Mishra[SUP] 7 [/SUP], Rajiv Kumar[SUP] 7 [/SUP], Dinesh Kumar Badyal[SUP] 8 [/SUP], Monika Sharma[SUP] 9 [/SUP], Mamta Singla[SUP] 10 [/SUP], Bikash Medhi[SUP] 11 [/SUP], Ajay Prakash[SUP] 11 [/SUP], Rupa Joshi[SUP] 11 [/SUP], Nabendu S Chatterjee[SUP] 12 [/SUP], Jerin Jose Cherian[SUP] 12 [/SUP], Ved Prakash Kamboj[SUP] 13 [/SUP], Nilima Kshirsagar[SUP] 14 [/SUP]
Affiliations
- PMID: 36531928
- PMCID: PMC9744681
- DOI: 10.1016/j.lansea.2022.100129
Abstract
India have seen more than 43 million confirmed cases of COVID-19 as of April 2022, with a recovery rate of 98.8%, resulting in a large section of the population including the healthcare workers (HCWs), susceptible to develop post COVID sequelae. This study was carried out to assess the nature and prevalence of medical sequelae following COVID-19 infection, and risk factors, if any, associated with them. Methods: This was an observational, multicenter cross-sectional study conducted at eight tertiary care centers. The consenting participants were HCWs between 12-52 weeks post discharge after COVID-19 infection. Data on demographics, medical history, clinical features of COVID-19 and various symptoms of COVID sequelae was collected through specific questionnaire. Finding: Mean age of the 679 eligible participants was 31.49 ± 9.54 years. The overall prevalence of COVID sequelae was 30.34%, with fatigue (11.5%) being the most common followed by insomnia (8.5%), difficulty in breathing during activity (6%) and pain in joints (5%). The odds of having any sequelae were most significantly higher among participants who had moderate to severe COVID-19 (OR 6.51; 95% CI 3.46 - 12.23) and lower among males (OR 0.55; 95% CI 0.39-0.76). Besides these, other predictors for having sequelae were age (≥ 45 years), presence of any comorbidity (especially hypertension and asthma), category of HCW (non-doctors vs doctors) and hospitalisation due to COVID-19. Interpretation: Approximately one-third of the participants experienced COVID sequelae. Severity of COVID illness, female gender, advanced age, co-morbidity were significant risk factors for COVID sequelae. Funding: This work is a part of Indian Council for Medical Research (ICMR)- Rational Use of Drugs network. No additional financial support was received from ICMR to carry out the work, for study materials, medical writing, and APC. FundingIndian Council of Medical Research (ICMR) through its Task Force Project on Rational Use of Medicines.
Keywords: ACE2, Angiotensin-converting enzyme 2; AE, Adverse events; Anxiety, and Stress Scale-21; BMI, Body mass index; CAD, Coronary artery disease; CI, Confidence interval; COVID sequelae; COVID-19; COVID-19, Corona virus disease 2019; CTRI, Clinical Trials Registry- India; DASS-21, Depression; ENT, Ear, nose, and throat; GERD, Gastroesophageal reflux disease; Govt. of India, OR; HCQ, Hydroxychloroquine; HCW, Health care worker; ICMR, Indian council of medical research; ICMR-RUMC; MOHFW, Ministry of Health and Family Welfare; NICE, National Institute for Health and Clinical Excellence; Odds ratio, PCOS; Polycystic Ovarian Disease, PLOG; Polymerase gamma-related disorders, p-value: Probability value; RHD, Rheumatic heart disease; RUMC, Rational use of medicine center; SARS-CoV-2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; WHO, World Health Organization; long COVID.